FDA extends review time for Biogen’s ALS treatment candidate


Shares of Biogen Inc. BIIB, -1.97% gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment for amyotrophic lateral sclerosis (ALS) by three months. The new decision date is April 25. Biogen’s stock is up 10.3% this year, while the S&P 500 SPX, -2.37% is down 24.8%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleFutures Movers: Oil ticks higher as traders weigh recession fears versus tight crude supplies
Next articleSchwab revenue and earnings per share rise more than forecast


Please enter your comment!
Please enter your name here